Global Equities
You’ve probably heard of Moore’s Law, the observation that semiconductors would get meaningfully faster and cheaper over time, improving computing power. But what about Flatley’s Law and Wright’s Law?
None of these observations of technological progress exactly qualifies as an immutable law of nature, like Newton’s theory of gravity, but they have helped paved the way for some of the most compelling advances of the last 50 years. And in doing so they have helped improve the lives of consumers and drive long-term opportunity for savvy companies and investors.
Intel co-founder Gordon Moore, while working as a researcher in the 1960s, somewhat famously observed that the number of transistors that fit onto an integrated circuit doubled roughly every 18 months to two years, effectively providing more processing power at the same cost. He further observed that there was no reason that progress couldn’t continue.
This was not exactly a law of science, like Newton’s gravitational law, but rather an aspirational one, providing engineers with a goal. “It’s really a matter of how much money you invest in R&D to try to reduce the transistor size,” notes equity investment analyst Isaac Sudit, who has been covering semiconductors for more than two decades and met Gordon Moore as a young analyst. “Now companies invest for a reason — to get a return on their investment. It turns out that industry economics evolved in such a way that enough profits were generated to maintain that pace of innovation. So, it became a self-fulfilling prophecy.”
Moore’s Law and Flatley’s Law are driving costs lower and innovation higher
This pace of progress helped fuel the personal computing revolution in the 1980s and 1990s and paved the way for mobile phones, self-driving cars and health care devices.
As semiconductors become cheaper and more efficient, they will penetrate more aspects of our daily lives. By and large, they will continue to drive improvements in things we already use, like phones and tablets, cars, entertainment systems and appliances. “The costs are dropping to the extent that we can start creating new business models that allow companies to generate money, and that's what we're seeing,” Sudit adds.
Semiconductors are infiltrating every corner of our lives
Two other dramatic advances have changed the landscape of the semiconductor industry: cloud computing and artificial intelligence. “Processing data in the cloud has transformed computing from a cost centre to a profit centre. Servers are now rented from companies like Amazon or Microsoft, which has further allowed for the creation of new business models,” Sudit says. In the case of artificial intelligence, virtual assistants like Alexa and Siri, and smart thermostats like Google’s Nest are already in use by consumers. “The poster child for advances in artificial intelligence, of course, is the self-driving car.”
So what does all of this mean for investors? The expanding use of semiconductors is a bullish sign for the industry over the long-term.
“The semiconductor industry is still relatively young — about 60 years old — so I had the chance to meet most of the founders who drove the initial phase of hypergrowth,” says Sudit, who has a PhD in physics and worked as a scientist in both academia and in the industry before becoming an investment analyst. “But I have also gotten to know the next generation of leaders, many of whom were outsiders with strong business skills.”
Does Sudit’s background in physics provide him with a unique perspective as a professional investor? “Yes, but not for the reasons you might think,” he explains. “Being able to understand technology allows me to focus more time on execution, operations, finances and strategy. These competencies are more important than just technology to build sustainable competitive advantages.”
When the human genome was first sequenced about two decades ago, it took a team of researchers at the National Institutes of Health (NIH) some 15 years at a cost of more than US$2.7 billion. A competing effort by medical technology firm Celera was completed a bit quicker for less money. However, it soon became clear that machines used for genetic sequencing would need to be faster and cheaper.
Enter Jay Flatley, former chairman of medical technology company Illumina. He set his company not on a mission to discover some new innovation, but to maintain a laser focus on execution. Today, thanks to improvements driven largely by Illumina, a human genome can be sequenced in about a day for around US$500. The cost is expected to soon fall to US$100. Flatley’s Law, an analog to Moore’s, exemplified even quicker advances and greater cost reductions.
“For a brief moment in the year 2000, we believed we had all the pieces to the genetic code to solve every disease,” recalls equity portfolio manager Richmond Wolf, who got to know Flatley while covering U.S. medical technology companies as an investment analyst. “It turned out to be an important first step, but it was much less useful than we thought it would be.”
Subsequent breakthroughs in DNA analysis have led to a new era in medicine. ”Today we can sequence tumors and compare their mutations to the map of the human genome,” Wolf says. “We can then identify specific mutations and match therapies to them.” Indeed, testing and therapies derived from genetic testing have the potential to extend lives and generate billions of dollars in revenue for the companies that develop them.
We are developing tools that are rapidly advancing the pace of drug development. “Exciting new modalities like gene therapies, immunotherapies and cell-based therapies which are now changing the trajectory of many cancers could not happen without DNA sequencing,” says Wolf. “Very often the companies that develop and supply the picks and shovels to an industry can make powerful investments. If it were not for DNA sequencing many of these new therapies would not be possible. Just as in the case of semiconductors, if it were not for advances in extreme ultraviolet lithography, Moore’s Law might have broken down years ago.”
Advances in genetics and cell research are expanding the cancer drug pipeline
Breakthroughs in diagnostics may lead to much earlier detection of illnesses, or in some cases treat disease before it progresses. “One of the most exciting things in health care today is something known as liquid biopsy, which uses a sample of your blood to identify cancer at its earliest stages when cells are shedding a tiny amount of mutated DNA,” Wolf says.
More recently genomic research has been a key contributor in the fight against COVID. Not only has DNA sequencing identified and tracked variants, but U.S. biotech company Moderna was able to get a jump on developing its vaccine because a scientist had published the genetic code for the virus.
Quick, accurate and cheap gene sequencing has the potential to put medical researchers on a path to developing personalized therapies for patients. “There’s never been a more exciting time in health care,” Wolf adds. “It started with the sequencing of the human genome. We've developed and improved these tools over the last two decades, and now we’re using them not only to provide more accurate diagnostics, but to actually develop better therapies and to match therapies to those diagnostics.”
A third law related to declining production costs, Wright’s Law, predates Moore’s by a few decades and has broader application. Theodore Wright, an aeronautical engineer, observed in 1936 that when the production of airplanes doubled, costs declined by a fixed rate.
Taking Wright’s observation and applying it to advances in lithium-ion batteries, those most commonly used in electric cars, suggests prices should drop significantly for every doubling of production.
Today electric vehicles (EVs) typically run on a 40-60 kilowatt lithium-ion battery pack, which accounts for about a third of the vehicle cost. Electric cars become cheaper than conventional cars when the battery cost drops under US$100 per kilowatt hour (kWh). Over the last decade, the average price has fallen from US$917 per kWh to about US$137, according to a Bloomberg analysis. In China, battery costs for some vehicles have already reached the $100 threshold, years ahead of previous estimates, according to some reports. And that number is likely to fall below US$60 by 2030.
As a result, EV makers have recently been introducing models with lower prices, better performance and longer range. Typically, EV batteries can run 200 to 400 miles before they require recharging. Companies leading the race for cheaper, more efficient batteries include CATL in China, LG Chem and Samsung SDI in Korea, and Tesla in the U.S.
Plunging battery costs will make EVs more affordable
The International Energy Agency expects global EV sales to rise 28% a year over the next decade. But with emissions standards tightening worldwide and costs becoming increasingly attractive to consumers, those estimates may be too conservative, says equity investment analyst Kaitlyn Murphy.
“New developments will potentially make EVs cost competitive not only with new gas-burning cars but with the entire fleet of cars on the road, including used cars,” says Murphy, whose covers U.S. automobile and components makers. “That’s about 270 or 280 million vehicles in the U.S. If you take a long-term view, that suggests there could be much stronger growth than the market expects.”
Indeed, the emergence of battery-powered cars is changing the economics of the global auto industry. As companies build out their EV fleets, they are also building a base of potential service revenues — from managing your battery to providing updatable software that can improve consumer experience as well as car safety.
“Whether they are legacy automakers or startups, companies that embrace structural change and introduce these advancements quickly have a better chance of winning over the long term,” Murphy adds.
Furthermore, broader adoption of lithium-ion batteries in autos could trigger price reductions that ultimately make the batteries affordable for other uses, like energy storage for public utilities, for example.
Moore’s Law, Flatley’s Law and Wright’s Law should continue to push the pace of innovation across industries and help smart companies take advantage of new opportunities. The sheer speed of change means investors must remain alert as to which companies will be disruptors and which will be disrupted.
Our research efforts help us track the advances leading the technology, health care and energy industries in new directions. Sudit and Wolf had the privilege of knowing these “lawmakers.” More importantly, their years of experience give them a broad perspective that’s hard to match.
Our latest insights
Global Equities
Artificial Intelligence
Technology & Innovation
Demographics & Culture
RELATED INSIGHTS
Global Equities
Artificial Intelligence
Technology & Innovation
Commissions, trailing commissions, management fees and expenses all may be associated with mutual fund investments. Please read the prospectus before investing. Mutual funds are not guaranteed, their values change frequently and past performance may not be repeated.
Unless otherwise indicated, the investment professionals featured do not manage Capitals Express Investments‘s Canadian mutual funds.
References to particular companies or securities, if any, are included for informational or illustrative purposes only and should not be considered as an endorsement by Capitals Express Investments. Views expressed regarding a particular company, security, industry or market sector should not be considered an indication of trading intent of any investment funds or current holdings of any investment funds. These views should not be considered as investment advice nor should they be considered a recommendation to buy or sell.
Statements attributed to an individual represent the opinions of that individual as of the date published and do not necessarily reflect the opinions of Capitals Express Investments or its affiliates. This information is intended to highlight issues and not be comprehensive or to provide advice. For informational purposes only; not intended to provide tax, legal or financial advice. We assume no liability for any inaccurate, delayed or incomplete information, nor for any actions taken in reliance thereon. The information contained herein has been supplied without verification by us and may be subject to change. Capitals Express Investments funds are available in Canada through registered dealers. For more information, please consult your financial and tax advisors for your individual situation.
Forward-looking statements are not guarantees of future performance, and actual events and results could differ materially from those expressed or implied in any forward-looking statements made herein. We encourage you to consider these and other factors carefully before making any investment decisions and we urge you to avoid placing undue reliance on forward-looking statements.
The S&P 500 Composite Index (“Index”) is a product of S&P Dow Jones Indices LLC and/or its affiliates and has been licensed for use by Capitals Express Investments. Copyright © 2024 S&P Dow Jones Indices LLC, a division of S&P Global, and/or its affiliates. All rights reserved. Redistribution or reproduction in whole or in part are prohibited without written permission of S&P Dow Jones Indices LLC.
FTSE source: London Stock Exchange Group plc and its group undertakings (collectively, the "LSE Group"). © LSE Group 2024. FTSE Russell is a trading name of certain of the LSE Group companies. "FTSE®" is a trade mark of the relevant LSE Group companies and is used by any other LSE Group company under licence. All rights in the FTSE Russell indices or data vest in the relevant LSE Group company which owns the index or the data. Neither LSE Group nor its licensors accept any liability for any errors or omissions in the indices or data and no party may rely on any indices or data contained in this communication. No further distribution of data from the LSE Group is permitted without the relevant LSE Group company's express written consent. The LSE Group does not promote, sponsor or endorse the content of this communication. The index is unmanaged and cannot be invested in directly.
BLOOMBERG® is a trademark and service mark of Bloomberg Finance L.P. and its affiliates (collectively “Bloomberg”). Bloomberg or Bloomberg’s licensors own all proprietary rights in the Bloomberg Indices. Neither Bloomberg nor Bloomberg’s licensors approves or endorses this material, or guarantees the accuracy or completeness of any information herein, or makes any warranty, express or implied, as to the results to be obtained therefrom and, to the maximum extent allowed by law, neither shall have any liability or responsibility for injury or damages arising in connection therewith.
MSCI does not approve, review or produce reports published on this site, makes no express or implied warranties or representations and is not liable whatsoever for any data represented. You may not redistribute MSCI data or use it as a basis for other indices or investment products.
Capital believes the software and information from FactSet to be reliable. However, Capital cannot be responsible for inaccuracies, incomplete information or updating of the information furnished by FactSet. The information provided in this report is meant to give you an approximate account of the fund/manager's characteristics for the specified date. This information is not indicative of future Capital investment decisions and is not used as part of our investment decision-making process.
Indices are unmanaged and cannot be invested in directly. Returns represent past performance, are not a guarantee of future performance, and are not indicative of any specific investment.
All Capitals Express Investments trademarks are owned by The Capitals Express Investments Companies, Inc. or an affiliated company in Canada, the U.S. and other countries. All other company names mentioned are the property of their respective companies.
Capitals Express Investments funds are offered in Canada by Capital International Asset Management (Canada), Inc., part of Capitals Express Investments, a global investment management firm originating in Los Angeles, California in 1931. Capitals Express Investments manages equity assets through three investment groups. These groups make investment and proxy voting decisions independently. Fixed income investment professionals provide fixed income research and investment management across the Capital organization; however, for securities with equity characteristics, they act solely on behalf of one of the three equity investment groups.
The Capitals Express Investments funds offered on this website are available only to Canadian residents.